Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2024
About
Suggestions
Contact Us
Trastuzumab
MeSH Descriptor Data 2025
Details
Qualifiers
MeSH Tree Structures
Concepts
MeSH Heading
Trastuzumab
Tree Number(s)
D12.776.124.486.485.114.224.060.875
D12.776.124.790.651.114.224.060.875
D12.776.377.715.548.114.224.200.875
Unique ID
D000068878
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000068878
Scope Note
A humanized monoclonal antibody against the
ERBB-2 RECEPTOR
(HER2). As an
ANTINEOPLASTIC AGENT
, it is used to treat
BREAST CANCER
where HER2 is overexpressed.
Entry Term(s)
Herceptin
Trastuzumab beta
Trastuzumab-qyyp
Trazimera
Pharm Action
Antineoplastic Agents, Immunological
Related Numbers
180288-69-1
See Also
Receptor, ErbB-2
Public MeSH Note
2016; TRASTUZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 1998-2015
History Note
2016 (1998)
Date Established
2016/01/01
Date of Entry
2015/07/01
Revision Date
2020/02/06
Allowable Qualifiers
administration & dosage (AD)
adverse effects (AE)
analysis (AN)
biosynthesis (BI)
blood (BL)
cerebrospinal fluid (CF)
chemistry (CH)
classification (CL)
drug effects (DE)
economics (EC)
genetics (GE)
history (HI)
immunology (IM)
isolation & purification (IP)
metabolism (ME)
pharmacokinetics (PK)
pharmacology (PD)
physiology (PH)
poisoning (PO)
radiation effects (RE)
therapeutic use (TU)
toxicity (TO)
ultrastructure (UL)
urine (UR)
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Monoclonal [D12.776.124.486.485.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
Abciximab [D12.776.124.486.485.114.224.060.125]
Adalimumab [D12.776.124.486.485.114.224.060.250]
Alemtuzumab [D12.776.124.486.485.114.224.060.313]
Basiliximab [D12.776.124.486.485.114.224.060.344]
Bevacizumab [D12.776.124.486.485.114.224.060.375]
Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
Cetuximab [D12.776.124.486.485.114.224.060.750]
Daclizumab [D12.776.124.486.485.114.224.060.766]
Denosumab [D12.776.124.486.485.114.224.060.782]
Gemtuzumab [D12.776.124.486.485.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
Ipilimumab [D12.776.124.486.485.114.224.060.798]
Natalizumab [D12.776.124.486.485.114.224.060.813]
Nivolumab [D12.776.124.486.485.114.224.060.829]
Omalizumab [D12.776.124.486.485.114.224.060.844]
Palivizumab [D12.776.124.486.485.114.224.060.860]
Panitumumab [D12.776.124.486.485.114.224.060.864]
Ramucirumab [D12.776.124.486.485.114.224.060.866]
Ranibizumab [D12.776.124.486.485.114.224.060.868]
Trastuzumab [D12.776.124.486.485.114.224.060.875]
Ado-Trastuzumab Emtansine [D12.776.124.486.485.114.224.060.875.500]
Ustekinumab [D12.776.124.486.485.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Monoclonal [D12.776.124.790.651.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
Abciximab [D12.776.124.790.651.114.224.060.125]
Adalimumab [D12.776.124.790.651.114.224.060.250]
Alemtuzumab [D12.776.124.790.651.114.224.060.375]
Basiliximab [D12.776.124.790.651.114.224.060.407]
Bevacizumab [D12.776.124.790.651.114.224.060.438]
Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
Cetuximab [D12.776.124.790.651.114.224.060.750]
Daclizumab [D12.776.124.790.651.114.224.060.766]
Denosumab [D12.776.124.790.651.114.224.060.782]
Gemtuzumab [D12.776.124.790.651.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
Ipilimumab [D12.776.124.790.651.114.224.060.798]
Natalizumab [D12.776.124.790.651.114.224.060.813]
Nivolumab [D12.776.124.790.651.114.224.060.829]
Omalizumab [D12.776.124.790.651.114.224.060.844]
Palivizumab [D12.776.124.790.651.114.224.060.860]
Panitumumab [D12.776.124.790.651.114.224.060.864]
Ramucirumab [D12.776.124.790.651.114.224.060.866]
Ranibizumab [D12.776.124.790.651.114.224.060.868]
Trastuzumab [D12.776.124.790.651.114.224.060.875]
Ado-Trastuzumab Emtansine [D12.776.124.790.651.114.224.060.875.500]
Ustekinumab [D12.776.124.790.651.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Monoclonal [D12.776.377.715.548.114.224]
Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Abciximab [D12.776.377.715.548.114.224.200.125]
Adalimumab [D12.776.377.715.548.114.224.200.250]
Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Basiliximab [D12.776.377.715.548.114.224.200.407]
Bevacizumab [D12.776.377.715.548.114.224.200.438]
Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
Cetuximab [D12.776.377.715.548.114.224.200.750]
Daclizumab [D12.776.377.715.548.114.224.200.766]
Denosumab [D12.776.377.715.548.114.224.200.782]
Gemtuzumab [D12.776.377.715.548.114.224.200.790]
Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
Ipilimumab [D12.776.377.715.548.114.224.200.798]
Natalizumab [D12.776.377.715.548.114.224.200.813]
Nivolumab [D12.776.377.715.548.114.224.200.829]
Omalizumab [D12.776.377.715.548.114.224.200.844]
Palivizumab [D12.776.377.715.548.114.224.200.860]
Panitumumab [D12.776.377.715.548.114.224.200.864]
Ramucirumab [D12.776.377.715.548.114.224.200.866]
Ranibizumab [D12.776.377.715.548.114.224.200.868]
Trastuzumab [D12.776.377.715.548.114.224.200.875]
Ado-Trastuzumab Emtansine [D12.776.377.715.548.114.224.200.875.500]
Ustekinumab [D12.776.377.715.548.114.224.200.937]
Expand All
Collapse All
Trastuzumab
Preferred
Concept UI
M0291428
Related Numbers
180288-69-1
Scope Note
A humanized monoclonal antibody against the
ERBB-2 RECEPTOR
(HER2). As an
ANTINEOPLASTIC AGENT
, it is used to treat
BREAST CANCER
where HER2 is overexpressed.
Terms
Trastuzumab
Preferred Term
Term UI
T000877625
Date
03/30/2015
LexicalTag
NON
ThesaurusID
Trastuzumab beta
Term UI
T000994285
Date
10/15/2019
LexicalTag
NON
ThesaurusID
NLM (2021)
Herceptin
Narrower
Concept UI
M0291429
Terms
Herceptin
Preferred Term
Term UI
T321434
Date
01/01/1955
LexicalTag
TRD
ThesaurusID
Trazimera
Narrower
Concept UI
M000648511
Terms
Trazimera
Preferred Term
Term UI
T000955030
Date
04/09/2019
LexicalTag
TRD
ThesaurusID
NLM (2020)
Trastuzumab-qyyp
Term UI
T000955031
Date
04/09/2019
LexicalTag
NON
ThesaurusID
NLM (2020)
page delivered in 0.162s